Phase I/IIa Trial Evaluating Safety of LOAd703, an Armed Oncolytic Adenovirus for Pancreatic Cancer

Trial Profile

Phase I/IIa Trial Evaluating Safety of LOAd703, an Armed Oncolytic Adenovirus for Pancreatic Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs LOAd 703 (Primary) ; Gemcitabine; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Lokon Pharma
  • Most Recent Events

    • 12 Nov 2016 Status changed from not yet recruiting to recruiting.
    • 20 Sep 2016 Planned End Date changed from 1 Jan 2019 to 1 Aug 2019.
    • 20 Sep 2016 Planned primary completion date changed from 1 Apr 2018 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top